Open Access

Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial

logo

Date: 4 May 2023
Journal: European Heart Journal , Volume 44 , Issue 22 , Pages 1995 - 2005
Topic: CARDIOVASCULAR PHARMACOLOGY, HEART FAILURE, Acute Heart Failure
Authors: P. Martens , F. Verbrugge , J. Dauw , P. Nijst , E. Meekers , S. Augusto , J. Ter Maaten , L. Heylen , K. Damman , A. Mebazaa , G. Filippatos , F. Ruschitzka , W. Tang , M. Dupont , W. Mullens

ESC Journals

AbstractAims

Acetazolamide inhibits proximal tubular sodium and bicarbonate re-absorption and improved decongestive response in acute heart failure in the ADVOR trial. It is unknown whether bicarbonate levels alter the decongestive response to acetazolamide.

Methods and results

This is a sub-analysis of the randomized, double-blind, placebo-controlled ADVOR trial that randomized 519 patients with acute heart failure and volume overload in a 1:1 ratio to intravenous acetazolamide (500 mg/day) or matching placebo on top of standardized intravenous loop diuretics (dose equivalent of twice oral maintenance dose). The primary endpoint was complete decongestion after 3 days of treatment (morning of day 4). Impact of baseline HCO3 levels on the treatment effect of acetazolamide was assessed. : Of the 519 enrolled patients, 516 (99.4%) had a baseline HCO3 measurement. Continuous HCO3 modelling illustrated a higher proportional treatment effect for acetazolamide if baseline HCO3 ≥ 27 mmol/l. A total of 234 (45%) had a baseline HCO3 ≥ 27 mmol/l. Randomization towards acetazolamide improved decongestive response over the entire range of baseline HCO3 levels (P = 0.004); however, patients with elevated baseline HCO3 exhibited a significant higher response to acetazolamide [primary endpoint: no vs. elevated HCO3; OR 1.37 (0.79–2.37) vs. OR 2.39 (1.35–4.22), P-interaction = 0.065), with higher proportional diuretic and natriuretic response (both P-interaction < 0.001), greater reduction in congestion score on consecutive days (treatment × time by HCO3-interaction <0.001) and length of stay (P-interaction = 0.019). The larger proportional treatment effect was mainly explained by the development of diminished decongestive response in the placebo arm (loop diuretics only), both with regard to reaching the primary endpoint of decongestion as well as reduction in congestion score. Development of elevated HCO3 further worsened decongestive response in the placebo arm (P-interaction = 0.041). A loop diuretic only strategy was associated with an increase in the HCO3 during the treatment phase which was prevented by acetazolamide (day 3: placebo 74.8% vs. acetazolamide 41.3%, P < 0.001).

Conclusion

Acetazolamide improves decongestive response over the entire range of HCO3 levels; however, the treatment response is magnified in patients with baseline or loop diuretic-induced elevated HCO3 (marker of proximal nephron NaHCO3 retention) by specifically counteracting this component of diuretic resistance.

Page viewed 35 times

About the contributors

Pieter Martens

Role: Author

Frederik H Verbrugge

Role: Author

Jeroen Dauw

Role: Author